Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02619994Phase 2Completed

Treatment Shortening of MDR-TB Using Existing and New Drugs

Role: collaborator

NCT04485156Phase 3Not Yet Recruiting

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Role: collaborator

NCT00816426Phase 1Completed

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Role: collaborator

NCT03934034Not Yet Recruiting

A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.

Role: collaborator

NCT00341601Completed

Multi-Drug Resistant Tuberculosis in Korea

Role: collaborator

NCT00374517Phase 2Withdrawn

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Role: collaborator

All 6 trials loaded